Podcasts about monoclonal antibodies

Medicare Advantage Minute announces 2019 statistics: 17% of MA claims were denied in that year but of those claims that were appealed, 57% were ultimately paid. In the "Your Medicare Benefits 2025" segment we learn how Medicare is likely to cover Monoclonal Antibodies when they are used for the treatment of early onset Alzheimer's disease. "Early onset" is described as symptoms appearing before age 65. Humana subsidiary CenterWell announced the purchase of bankrupt firm The Villages Health. Apparently they declared bankruptcy after discovering they owed hundreds of millions to Medicare. How does this sort of thing sneak up on a company? Finally, as alluded to in the headline of this episode, there was speculation about what might happen if a person insured by a High Deductible Medicare supplement. Would the family members tasked with paying the bills be burdened by extra accounting and check-writing duties in the event of a long period of disability? My answer? Unequivocally no! Contact me at: DBJ@MLMMailbag.com (Most severe critic: A+)                   Visit us on: BabyBoomer.ORG Inspired by: "MEDICARE FOR THE LAZY MAN 2025; Simplest & Easiest Guide Ever!" "MEDICARE DRUG PLANS: A SIMPLE D-I-Y GUIDE" For sale on Amazon.com. After enjoying the books, please consider returning to leave a short customer review to  help future readers. Official website: https://www.MedicareForTheLazyMan.com.

In this episode, Jonathan Sackier welcomes Claudio Cerchione, haematologist and researcher at the Hematology Unit, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. From his early interest in plasma cell disorders, Cerchione shares key insights into the evolution of multiple myeloma (MM) research, the rising role of minimal residual disease (MRD), and promising developments in monoclonal antibodies and CAR-T therapy. He also reflects on standout moments from recent European Hematology Association (EHA) Congress and American Society of Clinical Oncology (ASCO) Annual Meeting, and shares his hopes for the future of haematology.   Timestamps: 2:14: Memorable career experiences for Claudio   4:20 Biggest breakthrough in MM  5:10 Interest in plasma cell disorders  6:30 A surprising fact about multiple myeloma  7:40 Claudio's top choice for a dinner party guest  10:30 The importance of MRD in haematology  13:00 Monoclonal antibodies and CAR-T therapies  19:00 Current challenges  22:22 Claudio's key EHA and ASCO takeaways  28:30 Claudio's three magic wishes  

During the Lymphoma Hub Steering Committee meeting, Grzegorz Nowakowski, the Mayo Clinic, Rochester, US, chaired a discussion on anti-CD19 monoclonal antibodies for the treatment of DLBCL. This discussion also featured Gilles Salles, Sonali Smith, Ulrich Jäger, Catherine Thieblemont, Michael Dickinson, Francesc Bosch, Miles Prince, and Marek Trněný. Prior to the discussion, Nowakowski presented an overview of tafasitamab (Tafa), a CD19 monoclonal antibody, for the treatment of diffuse large B-cell lymphoma (DLBCL). He highlighted its mechanism of action and discussed the rationale for combining it with lenalidomide (Len) to improve immune-mediated antitumor activity. He reviewed data from the L-MIND trial, where Tafa-Len combination demonstrated a high overall response rate and durable remissions in relapsed/refractory (R/R) DLBCL. He also summarized real-world evidence showing consistent efficacy in patients meeting L-MIND eligibility criteria. Additional insights included the feasibility of using Tafa-Len prior to chimeric antigen receptor (CAR) T-cell therapy, the preservation of CD19 expression post-exposure, and the ongoing FrontMIND trial evaluating Tafa-Len + rituximab-cyclophosphamide-doxorubicin-vincristine-prednisone (R-CHOP) in previously untreated high-risk DLBCL.This educational resource is independently supported by Incyte. All content was developed by SES in collaboration with an expert steering committee; funders were allowed no influence on the content of this resource. Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.AbbVie's acquisition of Capstan Therapeutics for $2.1 billion highlights the increasing trend of mergers and acquisitions in the biopharmaceutical industry. This move gives AbbVie access to Capstan's novel in vivo CAR T therapy for autoimmune diseases. Meanwhile, Moderna's mRNA flu vaccine has shown promising results, outperforming the current standard shot in adults aged 50 and older. The FDA's deployment of an AI tool has sparked concerns regarding its readiness and legal implications.Following the approval of monoclonal antibodies for Alzheimer's disease, there has been a surge in deals related to research in this area. Wacker Biotech is now offering comprehensive biologics manufacturing services, covering everything from concept to commercialization.Additional updates cover various topics such as clinical trials progress, industry layoffs, and discussions on vaccine safety. Job opportunities within the biopharmaceutical sector are also available for those interested.

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Download the transcript here

Barry Quart, CEO of Connect Biopharma, is developing the next generation of monoclonal antibodies targeting inflammatory respiratory diseases such as COPD and asthma. Administered subcutaneously, their lead program targets IL-4 and has demonstrated the ability to rapidly improve airway function and reduce the incidence of acute exacerbations in these patients. Current treatments rely on steroids and bronchodilators, which do not address the underlying inflammatory causes, an area that has largely been under-addressed by other biologic developers. Barry explains, "Connect has been dedicated for quite a few years to designing next-generation monoclonal antibodies targeting inflammatory diseases. I joined the company last year and really kind of turned the ship towards a sole focus on our lead program, which is rademikibart, a second-generation Dupixent, a monoclonal antibody targeting IL-4, a really important target for certain inflammatory diseases." "IL-4 can be used as a monoclonal antibody targeting IL-4 for diseases such as atopic dermatitis, asthma, and COPD, as well as several other conditions. We're focused on asthma and COPD. So, inflammatory respiratory disease, because our product has some unique characteristics that are going to allow us to focus on an area that's really been completely ignored by other developers of biologics in the respiratory space, and specifically on patients having acute exacerbations."  #ConnectBiopharma #MonoclonalAntibody #IL4 #COPD #Asthma #AtopicDermatitis #InflammatoryDiseases #RespiratoryDiseases connectbiopharm.com Listen to the podcast here

Send us a textMarc Elia is the Founder of M28 Capital ( https://www.m28capital.com/ ), a healthcare sector investment fund, as well as Chairman of the Board of Invivyd ( https://www.invivyd.com/ ), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, beginning with SARS-CoV-2, by deploying a proprietary integrated technology platform, to create best in class monoclonal antibodies. In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates. Marc has a passion for investing in and developing innovative healthcare solutions, and dedicated much of his career to make a meaningful difference in human health, and advocate for the development of therapies that address unmet medical needs.Prior to M28, from January 2012 to September 2019, Marc served as a partner at Bridger Capital, an investment fund and has served on the Board of Directors of numerous companies.Prior to his time in the healthcare investment space, Marc served in Strategy and Corporate Development roles at Chiron Corporation, in Business Development at Protein Sciences Corporation, as well as in consulting at L.E.K. Consulting.Marc holds a B.A. in economics from Carleton College.#MarcElia #M28Capital #Invivyd #Biopharmaceuticals #InfectiousDiseases #SARSCoV2 #MonoclonalAntibodies #Immunocompromised #RareViralEpitopes #Pemivibart #PreExposureProphylaxis #Covid19 #EmergencyUseAuthorization #EUA #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #ViralPodcast #STEM #Innovation #Technology #Science #ResearchSupport the show

Cancer cells often have ways to hide from immune cells. Immunotherapy is a type of cancer treatment that helps our body's own defenses - "Natural Born Killers" - to more effectively fight the cancer. Learn how: https://bit.ly/3S5rAfAIn this Episode:01:37 - Relishing New York's Finer Moments04:47 - New York Cheesecake Recipe08:08 - Anna Quindlen - Gratitude for the Moments11:17 - Immunotherapy, How it Works and TypesCancer VaccinesCheckpoint InhibitorsT Cell TransferMonoclonal AntibodiesImmune System Modulators 21:58 - Discussion - Is this Pretty New?25:26 - Worn Hands28:31 - Outro#immunity #everydayisagift #cancervaccine #immunotherapy #tcelltherapy #checkpointinhibitors #monoclonalantibodies #immunesystemmodulators #newyorkcheesecake #cancertreatment #cancerchoices #cancertherapy Support the showGet show notes and resources at our website: every1dies.org. Facebook | Instagram | YouTube | mail@every1dies.org

Jo Cheah talks to Bronwyn Jenkins, consultant neurologist, about the role of calcitonin gene-related peptide (CGRP)–targeted therapies in migraine treatment. Bronwyn explains the difference between tension-type headaches and migraines, and outlines current treatment options. The conversation also covers adverse effects, patient eligibility, and other important considerations for prescribers. Read the full article in Australian Prescriber.

Carrie Dougherty, MD, FAHS and Jessica Ailani, MD review migraine abstracts from the 2024 European Headache Congress.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-navigating-the-baseline-mri-for-anti-a-monoclonal-antibodies/27038/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

CME credits: 1.25 Valid until: 25-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/clinical-conundrums-in-aria-1-navigating-the-baseline-mri-for-anti-a-monoclonal-antibodies/27038/ Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

Host: James R. Bateman, MD, MPH Guest: B. Joy Snider, MD, PhD Guest: Jerome A. Barakos, MD Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

Host: James R. Bateman, MD, MPH Guest: B. Joy Snider, MD, PhD Guest: Jerome A. Barakos, MD Amyloid-related imaging abnormalities (ARIA) represent a critical challenge in the management of Alzheimer's disease (AD), requiring a collaborative, interdisciplinary approach. This program, "Clinical Conundrums: Navigating Case Scenarios in Your Own Practice Setting," offers healthcare professionals concise, case-based microlearning episodes—each approximately 5 minutes long—designed to fit seamlessly into busy schedules. With real-world scenarios and expert-led discussions, this activity provides practical strategies to address diagnostic, monitoring, and therapeutic considerations, equipping participants to optimize patient care and outcomes in their respective fields.

In this week's episode we'll learn more about the significance of hypercalcemia in monoclonal gammopathy of undetermined significance, the role of neutrophil gelatinase-associated lipocalin in hemostasis, and the feasibility of combining CD19-targeted NK- or T-cell therapy with anti-CD19 monoclonal antibodies.Featured Articles:Approaching Hypercalcemia in Gammopathy of Undetermined Significance: Insights from the iStopMM study Deficiency of neutrophil gelatinase-associated lipocalin elicits Hemophilia-like bleeding and clotting disorder Anti-CD19 antibody cotreatment enhances serial killing activity of anti-CD19 CAR-T/-NK cells and reduces trogocytosis 

What are the downsides of pacemakers? Rethinking low-protein diets for chronic kidney disease; Bright light therapy and creatine alleviate depression; Withdrawal from World Health Organization assailed—but the U.S. can't afford to abdicate to its flawed dietary recommendations; Does a positive ANA blood test necessarily mean you're destined to develop an autoimmune disease? Unprecedented levels of sedative drug abuse among young people calls attention to “Anxious Generation."

The exorbitant cost of new drugs touted for psoriasis in direct-to-consumer ads highlights everything wrong with our medical system; When gastric bypass surgery sends blood sugar out of control; A campaign to ban ultra-processed foods from school meals may help alleviate nutritional threats to kids—but healthy eating begins at home; With winter viruses making the rounds, a remarkable supplement offers potent immune system support. 

Today, the discovery of antibodies targeting a new region of the malaria parasite that could serve as a promising target for drugs and vaccines.

Interview with Wei-Hsuan Lo-Ciganic, PhD, author of Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine. Hosted by Cynthia E. Armand, MD. Related Content: Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine

Interview with Wei-Hsuan Lo-Ciganic, PhD, author of Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine. Hosted by Cynthia E. Armand, MD. Related Content: Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine

In this episode, Jonathan sits down with Philip Smith to discuss groundbreaking advancements in gastroenterology, the impact of IBD research, and how his personal journey with Crohn's disease has influenced his career. From international guidelines to the role of digital platforms in healthcare, Smith offers a compelling insight into the future of gastrointestinal medicine.   Timestamps: (00:00)-Introduction (02:35)-Specialising in luminal gastroenterology (05:30)-IBD patient to practitioner (11:20)-Career highs and lows (17:40)-Smith's impactful IBD research (21:02)-The international approach to gastroenterology (25:39)-Screening colonoscopy (29:49)-Advancements and future priorities for IBD care (37:37)- Leveraging social media to engage with the gastroenterology community (43:30)-Identifying high-impact studies as EiC (49:06)-Three wishes for healthcare

In this episode, host Dr. Marc Dubin speaks with Dr. Peter Manes. They discuss the recently published Original Article: “Assessment of conflicts of interest in literature on monoclonal antibodies for chronic rhinosinusitis with nasal polyposis using the Open Payments Database”. The full manuscript is available online in the International Forum of Allergy and Rhinology. Listen […]

Dr Funmi Okunola MD interviews Professor Nancy Klimas MD about her research into the use of Monoclonal Antibodies as a possible treatment for Long COVID. We have an exciting and exclusive breaking news item in this episode!REFERENCES1 Scheppke KA, Pepe PE, Jui J, Crowe RP, Scheppke EK, Klimas NG, Marty AM. Remission of severe forms of long COVID following monoclonal antibody (MCA) infusions: a report of signal index cases and call for targeted research. The American Journal of Emergency Medicine. 2024 Jan 1;75:122-7.2 Zuo W, He D, Liang C, Du S, Hua Z, Nie Q, Zhou X, Yang M, Tan H, Xu J, Yu Y. The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China. The Lancet Infectious Diseases. 2024 Apr 22.3 Hope & Help for Fatigue and Chronic Illness - The Institute For Neuro-Immune Medicine Podcast4 Appelman B, Charlton BT, Goulding RP, Kerkhoff TJ, Breedveld EA, Noort W, Offringa C,Bloemers FW, van Weeghel M, Schomakers BV, Coelho P., Wüst Rob.C Muscle abnormalitiesworsen after post-exertional malaise in long COVID. Nature communications. 2024Jan 4;15(1):1-5

On this episode of Health 411, host Dr. Jonathan Karp and student producer Marina JB Are joined by Dr. Riggs, professor of Immunology at Rider University!

Alongside Cochrane Reviews of the effects of original drugs for the treatment of some diseases, reviews are starting to appear of the effects of biosimilars for these drugs. In this podcast, Roses Parker, Cochrane's Commissioning Editor tells us about the evidence in one of these reviews, published in November 2024, which considers biosimilar monoclonal antibodies for the treatment of patients with cancer.

Alongside Cochrane Reviews of the effects of original drugs for the treatment of some diseases, reviews are starting to appear of the effects of biosimilars for these drugs. In this podcast, Roses Parker, Cochrane's Commissioning Editor tells us about the evidence in one of these reviews, published in November 2024, which considers biosimilar monoclonal antibodies for the treatment of patients with cancer.

Join pediatrician Rachel Schultz, DO and Ob/Gyn Renda Knapp, MD as they discuss the RSV vaccine for babies and pregnant women. Why is this vaccine important? What is the difference between the vaccine for babies and the one for women? Learn about why RSV is dangerous for babies in particular.

RSV stands for respiratory syncytial virus, a common respiratory virus that usually causes upper respiratory illness with mild, cold-like symptoms. For some groups, like infants, RSV can be a severe lower respiratory tract illness. With no licensed vaccine available for babies, there are two options for protection against RSV. One option is a maternal RSV vaccine during pregnancy between 32 and 37 weeks from September through January. The other option is monoclonal antibodies administered to newborns within a week after birth. The vaccine and antibodies for RSV are both relatively newly approved treatments. This episode examines the available research to evaluate the safety and efficacy of these options so you can make an informed decision for yourself and your baby.     Thank you to our sponsors   Zahler goes above and beyond to use high-quality bioavailable ingredients like the active form of folate, bioavailable iron, and omega 3s. The Zahler Prenatal +DHA is my #1 recommendation for a high-quality prenatal vitamin.In October 2024, you can save 40% off the Zahler Prenatal +DHA on Amazon with the code PREPOD40. You can always see the current promo code for the Zahler prenatal vitamin by clicking here.   Try AG1 and get a FREE 1-year supply of immune-supporting Vitamin D AND 5 FREE AG1 travel packs with your first purchase. That's a $48 value for FREE! Just one daily scoop provides whole-body benefits like gut, immune, and stress support. AG1 sources bioavailable ingredients that actually work with your body. Plus, their formula has all non-GMO ingredients and contains no added sugar. With AG1, I know I am filling any nutrient gaps and supporting my gut for healthy digestion. (As a friendly reminder, pregnant or nursing women should seek professional medical advice before taking this or any other dietary supplement.)     Read the full article and resources that accompany this episode.      Join Pregnancy Podcast Premium to access the entire back catalog, listen to all episodes ad-free, get a copy of the Your Birth Plan Book, and more.     Check out the 40 Weeks podcast to learn how your baby grows each week and what is happening in your body. Plus, get a heads up on what to expect at your prenatal appointments and a tip for dads and partners.     For more evidence-based information, visit the Pregnancy Podcast website.

On this episode of Health 411, host Dr. Jonathan Karp and student producer Marina JB are joined by Professor of Biology and Behavioral Neuroscience at Rider University, Dr. Riggs. Tune in to learn about monoclonal antibodies, an important component of many medications and diagnostic processes!

We are BACK for SEASON FIVE of the pod! In this episode, Dr. Jessica Steier and Dr. Sarah Scheinman discuss Alzheimer's disease and cognitive decline. They cover essential topics including the definition and symptoms of Alzheimer's, the genetic and epigenetic basis of the disease, brain changes associated with Alzheimer's, risk factors such as age, genetics, and lifestyle, modifiable risk factors and prevention strategies, and current treatments and their controversies. The scientists emphasize that maintaining overall health is crucial for brain health. They recommend a combination of lifestyle choices that promote general well-being, which in turn support cognitive health. They explore various treatment options, including cholinesterase inhibitors, NMDA receptor antagonists, and monoclonal antibodies targeting amyloid beta. The conversation highlights the ongoing debates about treatment efficacy and the need for further research. The episode aims to provide valuable insights and alleviate fears surrounding Alzheimer's disease. It concludes with a rapid-fire Q&A segment addressing listeners' questions. All our sources from this episode are available at: https://www.unbiasedscipod.com/episodes/dont-you-forget-about-me-unraveling-alzheimers (00:01) Music and Season Five Welcome (04:30) Introducing Dr. Sarah Scheinman and the Topic of Alzheimer's (07:49) Understanding Alzheimer's Disease and Its Symptoms (10:50) The Genetic and Epigenetic Basis of Alzheimer's (18:23) Risk Factors for Alzheimer's: Age, Genetics, and Lifestyle (26:02) The Role of Amyloid Plaques and Tau Tangles in Alzheimer's (30:37) Promoting Early Diagnosis and Intervention for Alzheimer's (35:21) Breaking Down the Stigma and Building Scientific Literacy (41:51) Treatments for Alzheimer's Disease (46:27) Monoclonal Antibodies and Controversy (53:50) Diagnosing Alzheimer's Disease (55:32) Final Thoughts: Q&A: Common Questions About Alzheimer's Disease Interested in advertising with us? Please reach out to advertising@airwavemedia.com, with “Unbiased Science” in the subject line. PLEASE NOTE: The discussion and information provided in this podcast are for general educational, scientific, and informational purposes only and are not intended as, and should not be treated as, medical or other professional advice for any particular individual or individuals. Every person and medical issue is different, and diagnosis and treatment requires consideration of specific facts often unique to the individual. As such, the information contained in this podcast should not be used as a substitute for consultation with and/or treatment by a doctor or other medical professional. If you are experiencing any medical issue or have any medical concern, you should consult with a doctor or other medical professional. Further, due to the inherent limitations of a podcast such as this as well as ongoing scientific developments, we do not guarantee the completeness or accuracy of the information or analysis provided in this podcast, although, of course we always endeavor to provide comprehensive information and analysis. In no event may Unbiased Science or any of the participants in this podcast be held liable to the listener or anyone else for any decision allegedly made or action allegedly taken or not taken allegedly in reliance on the discussion or information in this podcast or for any damages allegedly resulting from such reliance. The information provided herein do not represent the views of our employers. Learn more about your ad choices. Visit megaphone.fm/adchoices

David Liew speaks with geriatrician and dementia specialist Louise Waite about her article on new and emerging therapies for Alzheimer disease. Louise explains key biomarkers for Alzheimer disease, and the potentially disease-modifying monoclonal antibody therapies that have been approved by the FDA and are now being considered by the TGA in Australia. Read the full article by Louise in Australian Prescriber.

Kristin is joined by Professor Sanjay Swaminathan to talk all things MABs or monoclonal antibodies. Dr Sanjay Swaminathan is a Clinical Immunologist and Allergist, he is a Senior Staff Specialist and Head of the Department of Immunology and Allergy at Westmead and Blacktown Hospitals.

—--

David Liew talks to gastroenterologist Varan Perananthan about his article on diagnosis and management of eosinophilic oesophagitis (EoE). Varan explains the causes and symptoms of EoE, why the prevalence has been increasing, and how to differentiate EoE from gastro-oesophageal reflux disease. Also discussed are dietary approaches for identifying food triggers and pharmacological treatments for EoE. Read the full article by Varan and his co-author, Rebecca Burgell, in Australian Prescriber.

My book Reframe Your Brain, available now on Amazon https://tinyurl.com/3bwr9fm8 Find my "extra" content on Locals: https://ScottAdams.Locals.com Content: Politics, Climate Change Worries, Expert Distrust, ChatGPT George Floyd, AI Narrative Programming, Food Lobby Spending, Monoclonal Antibodies, Whole Food Diets, Working Moms Microdosing, Military Base Penetrations, Trump NYC Trial, Trump Libertarian Convention, Bitcoin Elizabeth Warren, Ross Ulbricht, Ana Navarro, RFK Jr., Hillary Clinton, Dave Chappelle, Half-pinion, Ron Brownstein, James Carville, Biden West Point, Hoax Debunking AI, Scott Adams ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ If you would like to enjoy this same content plus bonus content from Scott Adams, including micro-lessons on lots of useful topics to build your talent stack, please see scottadams.locals.com for full access to that secret treasure. --- Support this podcast: https://podcasters.spotify.com/pod/show/scott-adams00/support

TNF-α Inhibitors and Monoclonal Antibodies mABs (WBH with Dr. Saleeby Ep. 17) Learn more about Whole Body Health: https://covid19criticalcare.com/courses/whole-body-health-with-dr-saleeby/ In this episode of Whole Body Health, Dr. JP Saleeby discusses TNF-α inhibitors and monoclonal antibodies (mABs) as treatments for autoimmune diseases like Crohn's disease and Rheumatoid Arthritis. Learn what TNF-α blockers are, their uses, and alternatives available. Dr. Saleeby shares concerns about the newness of some mABs, the lack of extensive safety data, and potential side effects. We'll also learn about the risks associated with anti-TNF therapy, including reduced immunity leading to infections such as tuberculosis and histoplasmosis, and the possibility of developing certain cancers and autoimmune conditions. Dr. Saleeby emphasizes the importance of being informed about these treatments, their adverse side effects, and why careful consideration is needed before starting therapy with TNF-α inhibitors and monoclonal antibodies Dr. JP Saleeby | Carolina Holistic Medicine
 https://carolinaholisticmedicine.com/ Dr. JP Saleeby's Substack | Yusuf's Substack
 https://jpsaleebymd.substack.com/ The FLCCC Alliance is a healthcare nonprofit on a mission to restore trust, integrity, and the doctor-patient relationship. Get involved by clicking below: • Donate: https://geni.us/Donate-Today 
 • Follow: https://geni.us/Follow-FLCCC 
 • Protocols: https://geni.us/Treatment 
 • Webinar: https://geni.us/FLCCC-Webinar 
 • Shop: https://geni.us/Shop-FLCCC Disclaimer:
This video is not intended to provide assessment, diagnosis, treatment, or medical advice; it also does not constitute provision of healthcare services. The content provided in this video is for informational and educational purposes only. Please consult with a physician or healthcare professional regarding any medical or mental health related diagnosis or treatment. No information in this video should ever be considered as a substitute for advice from a healthcare professional.

Monoclonal antibodies are used to treat cancer. Or is it asthma? Skin conditions? Wait, didn't we use those for covid, too?? The answer is yes! Jody reviews the basic mechanism of these versatile medications as well as their naming conventions and a bit about how they are discovered. References: 1) Manis, J. Overview of therapeutic monoclonal antibodies. UpToDate. 2) Mayo Clinic Staff. Monoclonal antibody drugs for cancer: How they work. Retrieved from https://www.mayoclinic.org/diseases-conditions/cancer/in-depth/monoclonal-antibody/art-20047808

This episode is for people who are seeking guidance about how we shall live and work and be joyful together in the face of on-going pandemic. Our guest is Dayna Nuckolls, known online as The People's Oracle, creator of the Divination For Liberation Framework of Sidereal Astrology and The 7 Essential Needs™️. Dayna is a multi-oracle diviner, musician, writer, speaker, and teacher. I'm so excited for her new project: The People's Public Health Education Campaign. We're talking about the pandemic, we're talking about liberatory astrology, we're planning for a future that includes a grassroots collective care renaissance. I hope I'll see you at the organizing meeting!  The People's Public Health Education Campaign Info Meeting Wednesday, April 3, 2024 at 6pm Central via Zoom Register to attend (or to receive meeting materials if you can't attend in person): https://bit.ly/pphec2024   For questions please contact Dayna on Insta @PeoplesOracle or James @jameslpoteet www.ThePeoplesOracle.com Follow Dayna on Instagram and Twitter: @PeoplesOracle YouTube: www.YouTube.com/LynnDayna Get the 2024 Sidereal Astrology Guide: https://shop.ThePeoplesOracle.com/collections/2024   Mentioned in this Episode   StatsCan Report, Dec 2023: Experiences of Canadians with long-term symptoms following COVID-19   Nature Medicine: Higher health risks associated with each Covid re-infection: Acute and postacute sequelae associated with SARS-CoV-2 reinfection   Mask blocs   Ba-Zi Chinese predictive astrology   Covid-19 Monoclonal Antibodies - emergency use authorization   How to Survive a Plague, by David France   Clean Air Club of Chicago   *** Leave feedback for the show!   Learn more about The Numinous Network   Sign up for my newsletter  

Welcome to another episode of The Veterinary Roundtable! In this episode, the ladies tease Devyn about not knowing who Mr. Rogers is, show off their new podcast scrubs, clarify and answer inquiries from last episode, discuss their thoughts on the new Canine Parvovirus Monoclonal Antibodies treatment, and more!Do you have a question for The Veterinary Roundtable? Ask us on any social media platform or email harrison@kingmediamarketing.com!Episodes of The Veterinary Roundtable are on all podcast services along with video form on YouTube!Social Links: https://linktr.ee/allstarvetclinicTIMESTAMPSTIMESTAMPSIntro 00:00Devyn Doesn't Know Who Mr. Ro gers Is 00:30The Ladies Have New Podcast Scrubs 03:14Dr. King And Courtney Have Bingo Night 06:19Inquiries From Last Episode 08:20Case Collections 20:38Listener Question (@brraatt_) 35:02Outro 43:30

Aduhelm is a type of drug called a monoclonal antibody, and it's used to remove some of the aberrant proteins thought to cause Alzheimer's disease. Lolita Nidadavolu, a geriatrics expert at Johns Hopkins, says there is much to consider when … Who is a candidate for monoclonal antibodies for Alzheimer's disease? Elizabeth Tracey reports Read More »

Monoclonal antibodies for Alzheimer's disease, like the drug called Aduhelm, attach to aberrant proteins thought to be one cause of the disease, but they only stand to benefit a small number of the people who might be at risk. That's … Only a small percentage of people are candidates for monoclonal antibodies to treat Alzheimer's disease, Elizabeth Tracey reports Read More »

DISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.                                                  >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.                                                                                  Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. Hello, and welcome to "DITCH THE LAB COAT," the podcast that strips down medical science and uncovers the core of health issues. I'm your host, Dr. Mark Bonta, and this is episode-3 of our thought-provoking three-part series on Covid-19. Today, we sit with the esteemed Dr. Suman Chakrabarti, our head of infectious diseases at Trillium Health Partners in Mississauga, who will unravel the now, the next, and the nuanced complexities of the pandemic. Despite battling a mild runny nose himself, Dr. Chakrabarti breaks down for us the realities of immune suppression, the risks, the recovery, and the truth behind the social decisions impacting our lives.From the gravity of lockdowns on mental health, education, and the economy to the lessons that could shape future pandemics, we dive deep into the controversies. We'll critique the polarizing divides between vaxxers and anti-vaxxers, maskers and anti-maskers. We'll explore how the pandemic has pressed on the wounds of inequality and delayed essential health care. Dr. Chakrabarti presses on the importance of a balanced approach to illness, the understanding of contagiousness, and the necessity of humility and cooperation. We'll consider the ramifications of our actions and investigate how we can empower rather than instill fear. Strap in as we also discuss the future of vaccination, the promise of mRNA vaccines beyond COVID-19, and the crucial need for personal empowerment over mandatory government intervention.Join us as we cast off the lab coat, and glean valuable insights on adapting, innovating, and thriving amidst this pandemic and the ones to come. Remember, DITCH THE LAB COAT airs every Wednesday morning. Don't miss this engaging conversation with Dr. Suman Chakrabarti, right after this short break.05:37 Balancing safety and practicality in workplace precautions.06:58 Immune suppression varies, impacts differently, precautions necessary.11:17 Balancing work and health during Covid-19.15:01 Stay home if sick, adapt to changes.17:13 Pandemic viruses become less virulent over time.22:02 Friends welcome, risks of gathering acknowledged.26:30 Balancing spending priorities during pandemic response is crucial.28:20 Focus on mental health and healthcare sustainability.32:16 Concerns over pandemic response; need for improvement.35:54 Society should only be shut down when necessary.40:01 Duty and sacrifice emphasized in helping society.43:29 Summary: Discussion about past, present, and future pandemics.45:06 Learning from pandemic to shape future mindset.

Discover the lifesaving potential of monoclonal antibodies in the fight against canine parvovirus as Laurie Larson shares insights on this innovative treatment. We unravel the complexities of parvovirus and how traditional vaccines sometimes fall short due to maternal antibodies. Laurie takes us through the riveting findings of a pivotal study published in JAVMA, revealing the success of monoclonal antibodies in significantly boosting survival rates in dogs. This episode is a beacon of hope, shedding light on the urgent need for prompt intervention at the first sign of infection. For veterinarians seeking to navigate client communication about this groundbreaking treatment, our conversation offers indispensable advice. Together, we're rewriting the narrative on combating canine parvovirus.Full article: https://doi.org/10.2460/javma.23.09.0541INTERESTED IN SUBMITTING YOUR MANUSCRIPT TO JAVMA ® OR AJVR ® ? JAVMA ® : https://avma.org/JAVMAAuthors AJVR ® : https://avma.org/AJVRAuthorsFOLLOW US:JAVMA ® : Facebook: Journal of the American Veterinary Medical Association - JAVMA | Facebook Instagram: JAVMA (@avma_javma) • Instagram photos and videos Twitter: JAVMA (@AVMAJAVMA) / Twitter AJVR ® : Facebook: American Journal of Veterinary Research - AJVR | Facebook Instagram: AJVR (@ajvroa) • Instagram photos and videos Twitter: AJVR (@AJVROA) / Twitter JAVMA ® and AJVR ® LinkedIn: https://linkedin.com/company/avma-journals

In a paradigm-shifting discovery, researchers uncovered that B cells, not T cells, wield significant influence on orchestrating neurological damage in MS. Join UCSF Professor Dr. Stephen Hauser as he shares the remarkable odyssey from hurdles to triumphs of developing B cell monoclonal antibody treatment for multiple sclerosis.  Disease impact, safety concerns and personalization of MS treatment of these medications including Ocrevus (ocrelizumab), Kesimpta (ofatumumab) and Briumvi (ublituximab) are highlighted.  Brain-penetrant BTK inhibitor therapies that may offer more direct targeting of B cells within the central nervous system, potentially unlocking new possibilities in treating progressive forms of MS. Professor Heinz Wiendl explores the connection between Epstein-Barr virus infection of B cells and the initiation and progression of MS including trials investigating strategies to target EBV-infected B cells. Pioneering approaches like CAR-T therapy and brain shuttle techniques provide optimism for the next generation of MS treatment. Barry Singer MD, Director of The MS Center for Innovations in Care, interviews:  Stephen Hauser MD, Professor of Neurology at the University of California, San Francisco (UCSF) and Director of the UCSF Weill Institute for Neurosciences Heinz Wiendl MD, Professor of Neurology and Chair of the Department of Neurology at the University Hospital of Muenster in Germany

It's that time of year again - cold season. While sniffles and congestion are a hallmark of winter, there are a few respiratory viruses that can be far more serious. In this episode, Dr. Harjot Singh, an epidemiologist at NewYork-Presbyterian  and Weill Cornell Medicine, explains why we're more likely to get sick during the colder months and how to protect ourselves from the three major illnesses - COVID-19, the flu and RSV – that pose the biggest threat this time of year. Click here for the episode transcript.

Let's take a little walk down Vaccine Memory Lane. Do you remember how it felt when you got access to the first Covid vaccine in late 2020/early 2021? Julie remembers DRESSING UP to go and get her vaccine. (She wore a turkey hat with little Santa hats on its feet since it was close to the holidays).Now, do you remember last winter's TRIPLEDEMIC??How can we avoid the same situation this year? What are the options and recommendations for folks for prevention of flu, COVID, and RSV?Today we have invited our doctor friend and expert in Infectious Diseases to explain the viral landscape in the US in the autumn of 2023. After today's episode you will feel empowered to make your personal vaccine choices based on your risk factors, epidemiologic evidence, and straight-from-the-source data-backed recommendations from CHICAGO'S FAUCI HIMSELF!!Welcome, Dr. Rob Citronberg!You may remember Dr. Citronberg from our previous episode about Monkeypox, Covid and Polio posted almost exactly a year ago! Dr. Citronberg is the Executive Medical Director of Infectious Disease and Prevention at Advocate Aurora HealthMD from University of Connecticut, IM Residency and ID Fellowship at RUSHTrusted news source as Infectious Disease expert (catch him regularly on ABC Chicago!)Julie was afraid of him when she was a resident (til she did an ID rotation then they were besties)"Get your COVID vaccine when you can, don't worry too much about timing it perfectly. It's a step towards getting back to a normal life, protecting ourselves and our loved ones." - Rob Citronberg, MDIn this episode, you will be able to:Find out how vaccinations stand as the frontline defense against COVID-19, Flu, and RSV.Understand the significance of safeguarding pregnant people and infants through planned vaccinations.Find out how to create memorable and safe holiday gatherings during pandemic times.Learn to access the most credible and valuable health and public information from respected medical experts. Decide which vaccines this fall/winter are most important for you based on your individual risk factors. Determine whether masking in public makes sense for you.Key moments in this episode include:00:00:00 - Introduction, 00:02:16 - Vaccine Landscape, 00:07:43 - Variants and Vaccines, 00:10:10 - Impact of Prior Pandemic Restrictions, 00:11:48 - RSV Overview, 00:12:42 - Vaccine Recommendations, 00:14:22 - The Importance of COVID-19 Vaccines, 00:16:01 - Transition to Annual COVID Shots vs "Boosters", 00:17:46 - Targeting High-Risk Populations, 00:22:52 - RSV Vaccines for Infants and Pregnant People, 00:28:07 - Challenges with Vaccination Uptake, 00:29:17 - Monoclonal Antibodies as a Game Changer, 00:32:14 - Preventing Serious Illnesses in Newborns, 00:34:13 - Continued Interest in Vaccine Research, 00:37:06 - School Safety and Recommendations, 00:42:52 - "Work Culture and Changing Attitudes", 00:43:48 - "Changing Attitudes in the Medical Field", 00:45:20 - "Shift towards Work-Life Balance", 00:46:08 - "Handling Holiday Plans during the Pandemic", 00:51:17 - "Effects of Masks and Mask Mandates", 00:56:50 - Importance of Listening to Credentialed Experts, 00:57:29 - Recommended Source: Your Local Epidemiologist, 00:58:15 - Keeping a Low Profile, 00:59:18 - Call to Action: Share the Podcast, 01:00:15 - Importance of Vaccination, Dr. Citronberg recommends the following resources if you want to learn more about vaccines this fall:The CDC website, specifically...

In Episode 59 of Derms and Conditions, our host, James Q. Del Rosso, DO, continues his conversation with Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale University School of Medicine who performs specialized research on novel treatments and therapies. After discussing sarecycline for acne in part 1, the two switch gears to monoclonal antibodies.  Dr Bunick begins by discussing dupilumab, an IL-4 and IL-13 blocker with significant clinical efficacy and a favorable safety profile in treating atopic dermatitis (AD). He states that in a network meta-analysis, upadacitinib and abrocitinib were shown to be more effective at treating AD than dupilumab, but dupilumab was shown to be more efficacious than tralokinumab and lebrikizumab. He and Dr Del Rosso agree that despite being part of a similar class, each IL-13 blocker should be applied and understood individually. They note several cases where patients who responded poorly to dupilumab had a beneficial response to tralokinumab, despite having similar mechanisms of action. Next, they discuss IL-13 signaling, which is increased and more persistent in tissues compared to other cytokines. However, Dr Bunick explains that IL-4 has more potent signaling, so IL-13 isn't necessarily more clinically relevant. He notes that more research is required to further understand the structure-function mechanisms of cytokines in the cell. He then mentions the non-canonical receptor, aka the “decoy receptor”, for IL-13, which could also explain a difference in drugs within the same class. Dr Del Rosso concludes that switching from one IL-13 blocker to another in a patient who was initially unresponsive to treatment may be more favorable than escalating to an alternative class of medication. Dr Del Rosso then discusses Dr Bunick's recent publication that compared the adverse effects of common immunosuppressive drugs to those of upadacitinib and abrocitinib in the treatment of AD. While the study population that used the common immunosuppressives did have comorbidities outside of AD, Dr Bunick notes that the risk of adverse events still exists for those treatments in AD and is not present only in JAK inhibitors. Dr Del Rosso states that many risk factors can contribute to adverse events, and not all responsibility should be shifted to JAK inhibitors. Tune in to this episode to learn the complete details about monoclonal antibodies and JAK inhibitors!

“It's really important to look at where your target is and what the toxicities are associated with hitting that target. Make sure you include that thinking when you're talking about bispecifics,” ONS member Rowena (Moe) Schwartz, PharmD, BCOP, professor of pharmacy practice at the James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about the use of bispecific monoclonal antibodies in hematologic cancers and solid tumors.   You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD), which may be applied to the treatment ILNA category, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by September 1, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: The learner will report an increase in knowledge related to bispecific monoclonal antibodies in hematologic cancers and solid tumors.  Episode Notes  Complete this evaluation for free NCPD.  ONS Voice drug reference sheets and FDA announcements about bispecific anticancer therapies  ONS resources for cytokine release syndrome  Oncology Nursing Podcast Episode 176: Oncologic Emergencies 101: Cytokine Release Syndrome  Clinical Journal of Oncology Nursing article: STAT: Cytokine Release Syndrome  Clinical Practice Resource  Clinical Practice Video  Huddle Card™  Cancer article: The BiTE (Bispecific T-Cell Engager) Platform: Development and Future Potential of a Targeted Immuno-Oncology Therapy Across Tumor Types  Pharmaceutics article: Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question  U.S. Food and Drug Administration label search for package inserts  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From Today's Episode  “When we talk about bispecifics, we need to really pay attention to both the target on the cancer and the target for T-cell engaging, because that impacts both efficacy but also toxicity.” TS 4:20  “If you really look deep into the clinical trials, often the patients that are receiving these agents in clinical trials have had more than the required three or four lines of treatment. They may have had five or more lines of treatment. So it's really important to kind of look at where it sits right now, knowing, of course, that that's an evolving target.” TS 7:13  “One of the things I think can be missed, at times, is the fact that you need to consider the toxicities associated with your target on the cancer cell.” TS 10:06  “In terms of mitigating risk, there's been two major ways that have been done. One is a step-up dose schedule, and so one of the key things I would say: If you're not familiar with an agent that you're going to be administering, it's really important to review the entire step-up scheme because it's different for each agent. In some cases, patients need to be admitted to the hospital for the entire step-up strategy. Other times it's just the first dose. So it's really important to look at that.” TS 11:58  “I think we're going to get to the point where our teaching strategy is going to have to be somewhat tailored to the agent we're giving. So, how the drug is given during the step-up, what the subsequent cycling is going to be, whether it's going to be a Q21-day cycle or a weekly dosing administration or every-two-week administration after a certain point. So, I think some understanding of what to expect going forward because these are drugs that are given continually in most situations and so it's important for people to know what to expect.” TS 14:25  “I think we're going to see bispecifics that perhaps engage other aspects of the immune system besides CD3. In fact, those are in clinical trials. And I do believe that we're going to see these more and more developed for cancers beyond the hematologic malignancies. There's a lot of work being done at looking at targets that we know are helpful targets in certain cancers. And I think we'll see more drugs approved beyond the myeloma and the lymphoma and the leukemia space.” TS 20:42 

In this interview, dementia expert Gil D. Rabinovici, MD, discusses monoclonal antibodies that target beta-amyloid–-including a recent phase 3 trial of donanemab published in JAMA-–and reviews considerations for their use in patients with Alzheimer disease. Related Content: Amyloid-Targeting Monoclonal Antibodies for Alzheimer Disease Donanemab in Early Symptomatic Alzheimer Disease